[Studies on antiphlogistic effects of fibrinolysin inhibitors].
D000588:Amines / Q000627:therapeutic use; D062365:Aminobenzoates / Q000627:therapeutic use; D000614:Aminocaproates / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000032:analysis / Q000494:pharmacology / Q000627:therapeutic use*; D007611:Aprotinin / Q000032:analysis / Q000494:pharmacology / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy*; D005260:Female; D005557:Formaldehyde; D006099:Granuloma / Q000139:chemically induced / Q000188:drug therapy*; D006634:Histamine H1 Antagonists; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy*; D007705:Kinins / Q000037:antagonists & inhibitors; D008722:Methods; D011480:Protease Inhibitors; D051381:Rats; D012871:Skin Diseases / Q000188:drug therapy*; D013460:Sulfur Isotopes
D000588:Amines; D062365:Aminobenzoates; D000614:Aminocaproates; D000893:Anti-Inflammatory Agents; D000933:Antifibrinolytic Agents; D003509:Cyclohexanecarboxylic Acids; D006634:Histamine H1 Antagonists; D007705:Kinins; D011480:Protease Inhibitors; D013460:Sulfur Isotopes; D005557:Formaldehyde; D007611:Aprotinin
Untersuchungen zur antiphlogistischen Wirkung von Fibrinolyseinhibitoren.